Pfizer raised its full-year adjusted EPS guidance to $3.00-$3.15 from $2.90-$3.10 after reporting better-than-expected Q3 results. The pharma giant reaffirmed revenue guidance of $61-$64 billion and said it remains on track to achieve $7.2 billion in net cost savings by 2027, despite tariff impacts.